CA2219299A1 - P-40, un nouveau membre de la famille des genes de resistance multiple aux medicaments - Google Patents

P-40, un nouveau membre de la famille des genes de resistance multiple aux medicaments Download PDF

Info

Publication number: CA2219299A1
Authority: CA; Canada
Prior art keywords: annexin; nucleic acid; mdr; cell; cells
Prior art date: 1997-10-24
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA 2219299

Other languages

English (en)

Inventor

Elias Georges

Ying Wang

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Individual

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-10-24

Filing date

1997-10-24

Publication date

1999-04-24

1997-10-24 Application filed by Individual filed Critical Individual

1997-10-24 Priority to CA 2219299 priority Critical patent/CA2219299A1/fr

1998-10-26 Priority to CA002308548A priority patent/CA2308548A1/fr

1998-10-26 Priority to PCT/CA1998/000992 priority patent/WO1999021980A1/fr

1998-10-26 Priority to EP98949842A priority patent/EP1025225A1/fr

1998-10-26 Priority to AU96174/98A priority patent/AU9617498A/en

1999-04-24 Publication of CA2219299A1 publication Critical patent/CA2219299A1/fr

Status Abandoned legal-status Critical Current

Links

108700041567 MDR Genes Proteins 0.000 title abstract description 9
210000004027 cell Anatomy 0.000 claims abstract description 150
150000007523 nucleic acids Chemical class 0.000 claims abstract description 63
108090000623 proteins and genes Proteins 0.000 claims abstract description 62
230000036457 multidrug resistance Effects 0.000 claims abstract description 61
102000039446 nucleic acids Human genes 0.000 claims abstract description 50
108020004707 nucleic acids Proteins 0.000 claims abstract description 50
238000000034 method Methods 0.000 claims abstract description 49
230000000692 anti-sense effect Effects 0.000 claims abstract description 7
108090000663 Annexin A1 Proteins 0.000 claims description 77
108050008874 Annexin Proteins 0.000 claims description 74
102000000412 Annexin Human genes 0.000 claims description 73
102000004145 Annexin A1 Human genes 0.000 claims description 57
229940079593 drug Drugs 0.000 claims description 49
239000003814 drug Substances 0.000 claims description 49
108020004414 DNA Proteins 0.000 claims description 34
239000000523 sample Substances 0.000 claims description 28
239000013598 vector Substances 0.000 claims description 26
239000002773 nucleotide Substances 0.000 claims description 21
125000003729 nucleotide group Chemical group 0.000 claims description 20
108090000765 processed proteins & peptides Proteins 0.000 claims description 15
108091028043 Nucleic acid sequence Proteins 0.000 claims description 14
102000004196 processed proteins & peptides Human genes 0.000 claims description 13
229920001184 polypeptide Polymers 0.000 claims description 12
125000003275 alpha amino acid group Chemical group 0.000 claims description 10
230000000694 effects Effects 0.000 claims description 9
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 6
239000011575 calcium Substances 0.000 claims description 6
229910052791 calcium Inorganic materials 0.000 claims description 6
230000000295 complement effect Effects 0.000 claims description 6
238000009396 hybridization Methods 0.000 claims description 6
150000003384 small molecules Chemical class 0.000 claims description 3
229940127291 Calcium channel antagonist Drugs 0.000 claims description 2
239000000480 calcium channel blocker Substances 0.000 claims description 2
150000001875 compounds Chemical class 0.000 claims 9
239000013068 control sample Substances 0.000 claims 2
244000052769 pathogen Species 0.000 claims 2
230000001717 pathogenic effect Effects 0.000 claims 2
210000004102 animal cell Anatomy 0.000 claims 1
239000002738 chelating agent Substances 0.000 claims 1
239000003937 drug carrier Substances 0.000 claims 1
230000002538 fungal effect Effects 0.000 claims 1
210000005260 human cell Anatomy 0.000 claims 1
230000002401 inhibitory effect Effects 0.000 claims 1
210000004962 mammalian cell Anatomy 0.000 claims 1
230000003071 parasitic effect Effects 0.000 claims 1
239000008194 pharmaceutical composition Substances 0.000 claims 1
102000004169 proteins and genes Human genes 0.000 abstract description 44
101001057606 Bacillus subtilis (strain 168) Elongation factor Tu Proteins 0.000 abstract description 32
238000001514 detection method Methods 0.000 abstract description 12
241001465754 Metazoa Species 0.000 abstract description 7
230000001225 therapeutic effect Effects 0.000 abstract description 5
210000004408 hybridoma Anatomy 0.000 abstract description 4
108020004711 Nucleic Acid Probes Proteins 0.000 abstract description 2
238000004166 bioassay Methods 0.000 abstract description 2
239000002853 nucleic acid probe Substances 0.000 abstract description 2
102000053602 DNA Human genes 0.000 description 32
230000014509 gene expression Effects 0.000 description 25
206010028980 Neoplasm Diseases 0.000 description 23
102100040006 Annexin A1 Human genes 0.000 description 19
238000011160 research Methods 0.000 description 18
238000003752 polymerase chain reaction Methods 0.000 description 17
102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 16
239000002299 complementary DNA Substances 0.000 description 16
101001017818 Homo sapiens ATP-dependent translocase ABCB1 Proteins 0.000 description 15
239000012528 membrane Substances 0.000 description 15
230000003321 amplification Effects 0.000 description 14
238000004458 analytical method Methods 0.000 description 14
201000011510 cancer Diseases 0.000 description 14
238000003199 nucleic acid amplification method Methods 0.000 description 14
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 12
102000004855 Multi drug resistance-associated proteins Human genes 0.000 description 12
108090001099 Multi drug resistance-associated proteins Proteins 0.000 description 12
238000012552 review Methods 0.000 description 12
229920002477 rna polymer Polymers 0.000 description 12
239000000020 Nitrocellulose Substances 0.000 description 11
239000012634 fragment Substances 0.000 description 11
238000000338 in vitro Methods 0.000 description 11
108020004999 messenger RNA Proteins 0.000 description 11
229920001220 nitrocellulos Polymers 0.000 description 11
206010059866 Drug resistance Diseases 0.000 description 10
230000001413 cellular effect Effects 0.000 description 10
238000001262 western blot Methods 0.000 description 10
230000002018 overexpression Effects 0.000 description 9
239000002246 antineoplastic agent Substances 0.000 description 8
229940041181 antineoplastic drug Drugs 0.000 description 8
108091034117 Oligonucleotide Proteins 0.000 description 7
239000013615 primer Substances 0.000 description 7
238000011282 treatment Methods 0.000 description 7
101710134681 40 kDa protein Proteins 0.000 description 6
239000000499 gel Substances 0.000 description 6
230000035945 sensitivity Effects 0.000 description 6
239000000243 solution Substances 0.000 description 6
238000013519 translation Methods 0.000 description 6
238000000636 Northern blotting Methods 0.000 description 5
229930012538 Paclitaxel Natural products 0.000 description 5
108020004511 Recombinant DNA Proteins 0.000 description 5
230000002776 aggregation Effects 0.000 description 5
238000004220 aggregation Methods 0.000 description 5
150000001413 amino acids Chemical class 0.000 description 5
230000001419 dependent effect Effects 0.000 description 5
238000007834 ligase chain reaction Methods 0.000 description 5
229960001592 paclitaxel Drugs 0.000 description 5
239000000047 product Substances 0.000 description 5
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 5
230000001052 transient effect Effects 0.000 description 5
239000003155 DNA primer Substances 0.000 description 4
241000196324 Embryophyta Species 0.000 description 4
229940009456 adriamycin Drugs 0.000 description 4
230000027455 binding Effects 0.000 description 4
230000004071 biological effect Effects 0.000 description 4
230000007423 decrease Effects 0.000 description 4
230000028023 exocytosis Effects 0.000 description 4
238000001114 immunoprecipitation Methods 0.000 description 4
239000002609 medium Substances 0.000 description 4
230000035772 mutation Effects 0.000 description 4
230000008569 process Effects 0.000 description 4
238000012216 screening Methods 0.000 description 4
239000000126 substance Substances 0.000 description 4
238000013518 transcription Methods 0.000 description 4
230000035897 transcription Effects 0.000 description 4
238000001890 transfection Methods 0.000 description 4
230000032258 transport Effects 0.000 description 4
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
108010085238 Actins Proteins 0.000 description 3
108091003079 Bovine Serum Albumin Proteins 0.000 description 3
108091026890 Coding region Proteins 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
239000004677 Nylon Substances 0.000 description 3
108020005187 Oligonucleotide Probes Proteins 0.000 description 3
240000004808 Saccharomyces cerevisiae Species 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 3
206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 3
239000006180 TBST buffer Substances 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
230000004075 alteration Effects 0.000 description 3
238000003556 assay Methods 0.000 description 3
238000005516 engineering process Methods 0.000 description 3
239000013604 expression vector Substances 0.000 description 3
239000000284 extract Substances 0.000 description 3
230000006870 function Effects 0.000 description 3
239000000203 mixture Substances 0.000 description 3
229920001778 nylon Polymers 0.000 description 3
239000002751 oligonucleotide probe Substances 0.000 description 3
230000026731 phosphorylation Effects 0.000 description 3
238000006366 phosphorylation reaction Methods 0.000 description 3
230000035479 physiological effects, processes and functions Effects 0.000 description 3
230000004481 post-translational protein modification Effects 0.000 description 3
230000002285 radioactive effect Effects 0.000 description 3
210000001995 reticulocyte Anatomy 0.000 description 3
239000007787 solid Substances 0.000 description 3
238000003146 transient transfection Methods 0.000 description 3
210000004881 tumor cell Anatomy 0.000 description 3
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 2
102000007469 Actins Human genes 0.000 description 2
108700028369 Alleles Proteins 0.000 description 2
241000972773 Aulopiformes Species 0.000 description 2
241000283707 Capra Species 0.000 description 2
230000004544 DNA amplification Effects 0.000 description 2
108010001336 Horseradish Peroxidase Proteins 0.000 description 2
108700026244 Open Reading Frames Proteins 0.000 description 2
101150065207 P40 gene Proteins 0.000 description 2
241000282320 Panthera leo Species 0.000 description 2
238000012300 Sequence Analysis Methods 0.000 description 2
238000002105 Southern blotting Methods 0.000 description 2
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
238000009825 accumulation Methods 0.000 description 2
238000007792 addition Methods 0.000 description 2
239000011543 agarose gel Substances 0.000 description 2
150000001408 amides Chemical class 0.000 description 2
230000001093 anti-cancer Effects 0.000 description 2
239000000427 antigen Substances 0.000 description 2
108091007433 antigens Proteins 0.000 description 2
102000036639 antigens Human genes 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
230000008901 benefit Effects 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
229940098773 bovine serum albumin Drugs 0.000 description 2
239000000969 carrier Substances 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
230000008859 change Effects 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
238000004891 communication Methods 0.000 description 2
231100000433 cytotoxic Toxicity 0.000 description 2
230000001472 cytotoxic effect Effects 0.000 description 2
238000012217 deletion Methods 0.000 description 2
230000037430 deletion Effects 0.000 description 2
239000005547 deoxyribonucleotide Substances 0.000 description 2
125000002637 deoxyribonucleotide group Chemical group 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
238000006073 displacement reaction Methods 0.000 description 2
229960004679 doxorubicin Drugs 0.000 description 2
DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
-1 fluoruphores Substances 0.000 description 2
238000010166 immunofluorescence Methods 0.000 description 2
238000011534 incubation Methods 0.000 description 2
230000000977 initiatory effect Effects 0.000 description 2
229910052816 inorganic phosphate Inorganic materials 0.000 description 2
208000032839 leukemia Diseases 0.000 description 2
239000003446 ligand Substances 0.000 description 2
239000000463 material Substances 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
239000002207 metabolite Substances 0.000 description 2
235000013336 milk Nutrition 0.000 description 2
239000008267 milk Substances 0.000 description 2
210000004080 milk Anatomy 0.000 description 2
238000010369 molecular cloning Methods 0.000 description 2
230000007170 pathology Effects 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
102000036213 phospholipid binding proteins Human genes 0.000 description 2
108091011000 phospholipid binding proteins Proteins 0.000 description 2
150000003904 phospholipids Chemical class 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
230000001737 promoting effect Effects 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
235000019515 salmon Nutrition 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
238000006467 substitution reaction Methods 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
230000009261 transgenic effect Effects 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
229960001722 verapamil Drugs 0.000 description 2
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 1
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
241000837181 Andina Species 0.000 description 1
108050005848 Annexin A10 Proteins 0.000 description 1
102100028117 Annexin A10 Human genes 0.000 description 1
102000014914 Carrier Proteins Human genes 0.000 description 1
241000699800 Cricetinae Species 0.000 description 1
108010017826 DNA Polymerase I Proteins 0.000 description 1
102000004594 DNA Polymerase I Human genes 0.000 description 1
108020003215 DNA Probes Proteins 0.000 description 1
239000003298 DNA probe Substances 0.000 description 1
230000006820 DNA synthesis Effects 0.000 description 1
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
238000009007 Diagnostic Kit Methods 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
244000040311 Eucharis candida Species 0.000 description 1
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 1
108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
102000005720 Glutathione transferase Human genes 0.000 description 1
108010070675 Glutathione transferase Proteins 0.000 description 1
108090000862 Ion Channels Proteins 0.000 description 1
102000004310 Ion Channels Human genes 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
101000959737 Mus musculus Annexin A1 Proteins 0.000 description 1
241000204031 Mycoplasma Species 0.000 description 1
241000204003 Mycoplasmatales Species 0.000 description 1
YFONKFDEZLYQDH-OPQQBVKSSA-N N-[(1R,2S)-2,6-dimethyindan-1-yl]-6-[(1R)-1-fluoroethyl]-1,3,5-triazine-2,4-diamine Chemical compound C[C@@H](F)C1=NC(N)=NC(N[C@H]2C3=CC(C)=CC=C3C[C@@H]2C)=N1 YFONKFDEZLYQDH-OPQQBVKSSA-N 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
206010061535 Ovarian neoplasm Diseases 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
108010089430 Phosphoproteins Proteins 0.000 description 1
102000007982 Phosphoproteins Human genes 0.000 description 1
108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
102100033237 Pro-epidermal growth factor Human genes 0.000 description 1
102100021923 Prolow-density lipoprotein receptor-related protein 1 Human genes 0.000 description 1
102000001253 Protein Kinase Human genes 0.000 description 1
102000003923 Protein Kinase C Human genes 0.000 description 1
108090000315 Protein Kinase C Proteins 0.000 description 1
239000012980 RPMI-1640 medium Substances 0.000 description 1
108091005682 Receptor kinases Proteins 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
241001415395 Spea Species 0.000 description 1
RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
101710183280 Topoisomerase Proteins 0.000 description 1
101710120037 Toxin CcdB Proteins 0.000 description 1
108700019146 Transgenes Proteins 0.000 description 1
241000251539 Vertebrata <Metazoa> Species 0.000 description 1
229940122803 Vinca alkaloid Drugs 0.000 description 1
108020005202 Viral DNA Proteins 0.000 description 1
239000002253 acid Substances 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
230000001464 adherent effect Effects 0.000 description 1
230000001919 adrenal effect Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
238000013019 agitation Methods 0.000 description 1
239000000556 agonist Substances 0.000 description 1
235000015107 ale Nutrition 0.000 description 1
125000005600 alkyl phosphonate group Chemical group 0.000 description 1
238000000137 annealing Methods 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000000843 anti-fungal effect Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
229940121375 antifungal agent Drugs 0.000 description 1
230000006907 apoptotic process Effects 0.000 description 1
238000002820 assay format Methods 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
238000000376 autoradiography Methods 0.000 description 1
108010005774 beta-Galactosidase Proteins 0.000 description 1
108091008324 binding proteins Proteins 0.000 description 1
230000008827 biological function Effects 0.000 description 1
229960002685 biotin Drugs 0.000 description 1
235000020958 biotin Nutrition 0.000 description 1
239000011616 biotin Substances 0.000 description 1
230000037396 body weight Effects 0.000 description 1
238000009835 boiling Methods 0.000 description 1
244000309466 calf Species 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
230000030833 cell death Effects 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
230000007248 cellular mechanism Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
239000003638 chemical reducing agent Substances 0.000 description 1
239000005081 chemiluminescent agent Substances 0.000 description 1
210000003737 chromaffin cell Anatomy 0.000 description 1
210000001366 chromaffin granule Anatomy 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
229940121657 clinical drug Drugs 0.000 description 1
238000010367 cloning Methods 0.000 description 1
239000013599 cloning vector Substances 0.000 description 1
238000011109 contamination Methods 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
239000006071 cream Substances 0.000 description 1
230000037029 cross reaction Effects 0.000 description 1
238000012258 culturing Methods 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
238000002405 diagnostic procedure Methods 0.000 description 1
230000036267 drug metabolism Effects 0.000 description 1
238000001035 drying Methods 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
238000009472 formulation Methods 0.000 description 1
230000004927 fusion Effects 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
239000011521 glass Substances 0.000 description 1
230000012010 growth Effects 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
238000007654 immersion Methods 0.000 description 1
238000010185 immunofluorescence analysis Methods 0.000 description 1
238000003125 immunofluorescent labeling Methods 0.000 description 1
239000012133 immunoprecipitate Substances 0.000 description 1
238000010874 in vitro model Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
210000004020 intracellular membrane Anatomy 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
238000002955 isolation Methods 0.000 description 1
238000002372 labelling Methods 0.000 description 1
238000011005 laboratory method Methods 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000002502 liposome Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
238000011068 loading method Methods 0.000 description 1
230000007774 longterm Effects 0.000 description 1
239000006210 lotion Substances 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
108010026228 mRNA guanylyltransferase Proteins 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
238000001466 metabolic labeling Methods 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
231100000350 mutagenesis Toxicity 0.000 description 1
229930014626 natural product Natural products 0.000 description 1
101150006061 neur gene Proteins 0.000 description 1
210000000440 neutrophil Anatomy 0.000 description 1
238000007899 nucleic acid hybridization Methods 0.000 description 1
239000002674 ointment Substances 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
244000045947 parasite Species 0.000 description 1
230000037361 pathway Effects 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
230000003285 pharmacodynamic effect Effects 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
239000013612 plasmid Substances 0.000 description 1
229910052697 platinum Inorganic materials 0.000 description 1
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
108060006633 protein kinase Proteins 0.000 description 1
230000006920 protein precipitation Effects 0.000 description 1
230000017854 proteolysis Effects 0.000 description 1
230000002797 proteolythic effect Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
108091008146 restriction endonucleases Proteins 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
239000002336 ribonucleotide Substances 0.000 description 1
125000002652 ribonucleotide group Chemical group 0.000 description 1
239000012723 sample buffer Substances 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000013605 shuttle vector Substances 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
239000007921 spray Substances 0.000 description 1
238000010186 staining Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
238000003239 susceptibility assay Methods 0.000 description 1
239000000725 suspension Substances 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
230000002103 transcriptional effect Effects 0.000 description 1
230000009466 transformation Effects 0.000 description 1
230000014621 translational initiation Effects 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
230000002792 vascular Effects 0.000 description 1
238000012800 visualization Methods 0.000 description 1
238000005406 washing Methods 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
239000002676 xenobiotic agent Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4721—Lipocortins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Zoology (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Toxicology (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Peptides Or Proteins (AREA)

CA 2219299 1997-10-24 1997-10-24 P-40, un nouveau membre de la famille des genes de resistance multiple aux medicaments Abandoned CA2219299A1 (fr)

Priority Applications (5)

Application Number	Priority Date	Filing Date	Title
CA 2219299 CA2219299A1 (fr)	1997-10-24	1997-10-24	P-40, un nouveau membre de la famille des genes de resistance multiple aux medicaments
CA002308548A CA2308548A1 (fr)	1997-10-24	1998-10-26	P-40/annexine i, proteines associees et leur role dans la resistance multiple aux anticancereux
PCT/CA1998/000992 WO1999021980A1 (fr)	1997-10-24	1998-10-26	P-40/annexine i, proteines associees et leur role dans la resistance multiple aux anticancereux
EP98949842A EP1025225A1 (fr)	1997-10-24	1998-10-26	P-40/annexine i, proteines associees et leur role dans la resistance multiple aux anticancereux
AU96174/98A AU9617498A (en)	1997-10-24	1998-10-26	P-40/annexin i and related proteins and their role in multidrug resistance

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CA 2219299 CA2219299A1 (fr)	1997-10-24	1997-10-24	P-40, un nouveau membre de la famille des genes de resistance multiple aux medicaments

Publications (1)

Publication Number	Publication Date
CA2219299A1 true CA2219299A1 (fr)	1999-04-24

Family

ID=4161689

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA 2219299 Abandoned CA2219299A1 (fr)	1997-10-24	1997-10-24	P-40, un nouveau membre de la famille des genes de resistance multiple aux medicaments

Country Status (4)

Country	Link
EP (1)	EP1025225A1 (fr)
AU (1)	AU9617498A (fr)
CA (1)	CA2219299A1 (fr)
WO (1)	WO1999021980A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2002544522A (ja)	1999-05-14	2002-12-24	マクギルユニバーシティー	タンパク質間相互作用並びに相互作用するタンパク質および相互作用部位のアミノ酸配列を同定する方法
WO2005027965A1 (fr) *	2003-09-24	2005-03-31	Peter Krammer	Anticorps diriges contre les annexines, leur utilisation a des fins therapeutiques et diagnostiques, utilisation des annexines a des fins therapeutiques et diagnostiques
EP1755646A2 (fr) *	2004-06-02	2007-02-28	Sidney Kimmel Cancer Center	Cibles vasculaires permettant de detecter, d'imager et de traiter la neoplasie ou la croissance neovasculaire
WO2007072221A2 (fr) *	2005-11-10	2007-06-28	Aurelium Biopharma Inc.	Agents therapeutiques anticancereux utilisant un marqueur de surface
GB201813137D0 (en)	2018-08-10	2018-09-26	Medannex Ltd	Cancer treatment with an antibody

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FI863626A0 (fi) *	1985-01-10	1986-09-09	Biogen Nv	Dna-sekvenser, rekombinant-dna -molekyler och foerfaranden foer framstaellning av polypeptider som liknar humant lipokortin.

1997
- 1997-10-24 CA CA 2219299 patent/CA2219299A1/fr not_active Abandoned
1998
- 1998-10-26 EP EP98949842A patent/EP1025225A1/fr not_active Withdrawn
- 1998-10-26 AU AU96174/98A patent/AU9617498A/en not_active Abandoned
- 1998-10-26 WO PCT/CA1998/000992 patent/WO1999021980A1/fr not_active Ceased

Also Published As

Publication number	Publication date
EP1025225A1 (fr)	2000-08-09
AU9617498A (en)	1999-05-17
WO1999021980A1 (fr)	1999-05-06

Publication	Publication Date	Title
ES2253756T3 (es)	2006-06-01	Familia de genes proteicos inhibidores de la apoptosis en mamiferos, cebadores, sondas y procedimiento de deteccion.
WO2000014228A1 (fr)	2000-03-16	Transporteur d'acides amines neutres et gene correspondant
EP0942972A2 (fr)	1999-09-22	Proteine e25a, ses procedes de production et d'utilisation
JP2003523207A (ja)	2003-08-05	Ｌｉｖ−１関連タンパク質、それをコードするポリヌクレオチド、及び癌の治療へのその利用
CA2215793C (fr)	2005-07-05	Utilisation de la proteine inhibitrice d'apoptose neuronale (naip)
Mourtada-Maarabouni et al.	2002	Candidate tumour suppressor LUCA-15 can regulate multiple apoptotic pathways
JP4314386B2 (ja)	2009-08-12	Ｂｃｌ−２調節因子（ＢＭＦ）配列及びアポトーシスの調節におけるそれらの使用
CA2219299A1 (fr)	1999-04-24	P-40, un nouveau membre de la famille des genes de resistance multiple aux medicaments
EP0900273A2 (fr)	1999-03-10	Famille de transporteurs d'anions organiques, acides nucleiques codant ceux-ci, cellules les comprenant et procedes d'utilisation associes
US6780604B2 (en)	2004-08-24	Mammalian pro-apoptotic Bok genes and their uses
US6908750B2 (en)	2005-06-21	Gene encoding HM1.24 antigen protein and promoter thereof
CA2308548A1 (fr)	1999-05-06	P-40/annexine i, proteines associees et leur role dans la resistance multiple aux anticancereux
JPWO1997032982A1 (ja)	1998-08-04	ヒト接着分子オクルディン
WO1999047671A2 (fr)	1999-09-23	Sequences d'adn codant pour la semaphorine-h et diagnostic du cancer metastatique
US6331412B1 (en)	2001-12-18	Methods and compounds for modulating male fertility
ES2242597T3 (es)	2005-11-16	Composiciones y procedimientos para el diagnostico y tratamiento de un tumor.
ES2378527T3 (es)	2012-04-13	Polipéptido ICBP90 y sus fragmentos, polinucleótidos que codifican dichos polipéptidos y aplicaciones para el diagnóstico y el tratamiento del cáncer
US20040248139A1 (en)	2004-12-09	Eit-6, a polypeptide encoded by an estrogen regulated gene
US20020076785A1 (en)	2002-06-20	Cyk-4 polypetides , DNA molecules encoding them and their use in screening methods
KR20010102996A (ko)	2001-11-17	메그-4 단백질
JPWO1999040190A1 (ja)	2002-10-08	ヒトｔｓｃ４０３遺伝子及びヒトｉｎｇ１ｌ遺伝子
WO2001097608A2 (fr)	2001-12-27	Polypeptides cyk-4, molecules d'adn codant ces polypeptides, et utilisation de ceux-ci dans des procedes de criblage
JPWO2002097088A1 (ja)	2004-09-09	精巣型カルニチントランスポーターとその遺伝子
JP4789822B2 (ja)	2011-10-12	ガンキリンの生物学的活性を有するポリペプチドに対する阻害剤を含んでなる癌治療剤
JPWO1999018201A1 (ja)	2001-04-10	ガンキリン

Legal Events

Date	Code	Title	Description
2000-10-24	FZDE	Dead